926 related articles for article (PubMed ID: 25963579)
1. Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.
Kruse G; Wong BJ; Duh MS; Lefebvre P; Lafeuille MH; Fastenau JM
Pharmacoeconomics; 2015 Oct; 33(10):1049-67. PubMed ID: 25963579
[TBL] [Abstract][Full Text] [Related]
2. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
3. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.
Achilla E; McCrone P
Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934
[TBL] [Abstract][Full Text] [Related]
4. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis.
Hartling L; Abou-Setta AM; Dursun S; Mousavi SS; Pasichnyk D; Newton AS
Ann Intern Med; 2012 Oct; 157(7):498-511. PubMed ID: 22893011
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
[TBL] [Abstract][Full Text] [Related]
8. What do large scale studies of medication in schizophrenia add to our management strategies?
Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
[TBL] [Abstract][Full Text] [Related]
10. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.
Heres S; Davis J; Maino K; Jetzinger E; Kissling W; Leucht S
Am J Psychiatry; 2006 Feb; 163(2):185-94. PubMed ID: 16449469
[TBL] [Abstract][Full Text] [Related]
11. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia.
Edwards NC; Pesa J; Meletiche DM; Engelhart L; Thompson AK; Sherr J; Dirani R
Curr Med Res Opin; 2008 Dec; 24(12):3341-55. PubMed ID: 18954497
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.
Leucht S; Komossa K; Rummel-Kluge C; Corves C; Hunger H; Schmid F; Asenjo Lobos C; Schwarz S; Davis JM
Am J Psychiatry; 2009 Feb; 166(2):152-63. PubMed ID: 19015230
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia.
Harvey RC; James AC; Shields GE
CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
[TBL] [Abstract][Full Text] [Related]
15. Selection of atypical antipsychotics for the management of schizophrenia.
Sprague DA; Loewen PS; Raymond CB
Ann Pharmacother; 2004 Feb; 38(2):313-9. PubMed ID: 14742771
[TBL] [Abstract][Full Text] [Related]
16. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis.
Pagsberg AK; Tarp S; Glintborg D; Stenstrøm AD; Fink-Jensen A; Correll CU; Christensen R
J Am Acad Child Adolesc Psychiatry; 2017 Mar; 56(3):191-202. PubMed ID: 28219485
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
[TBL] [Abstract][Full Text] [Related]
18. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ
Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
